Maven Securities’s Chemomab Therapeutics CMMB Stock Holding History

Maven Securities’s Portfolio CMMB Stock Details CMMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-31,641	Closed	-$3.63M	–	1097
2021 Q1	$3.63M	Buy	+31,641	New	+$6.3M	0.16%	121

Other funds holding CMMB

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

SWM

Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Maven Securities's CMMB Position: Q2 2021 in Review

Maven Securities sold out of Chemomab Therapeutics (CMMB) in Q2 2021, closing a stake of 31,641 shares — an estimated $3.63M sold.

Maven Securities first reported a position in CMMB in Q1 2021 and held it in 1 quarter. The position peaked at $3.63M in Q1 2021. 12 funds tracked by Wall St. Rank hold CMMB as of Q2 2021.

Maven Securities reported no remaining Chemomab Therapeutics position as of Q2 2021 after selling out during the quarter.
Maven Securities sold 31,641 Chemomab Therapeutics shares in Q2 2021, an estimated $3.63M.
Maven Securities first reported a position in Chemomab Therapeutics in Q1 2021 and held it in 1 quarter.
Maven Securities's Chemomab Therapeutics position peaked at $3.63M in Q1 2021.
12 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.